Clear All
11748 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
71288-0165-54 71288-0165 Nelarabine Nelarabine 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan 10, 2023 In Use
71288-0166-10 71288-0166 Pemetrexed disodium Pemetrexed 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
71288-0166-91 71288-0166 Pemetrexed disodium Pemetrexed 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
71288-0166-92 71288-0166 Pemetrexed disodium Pemetrexed 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
71288-0167-50 71288-0167 Pemetrexed disodium Pemetrexed 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
71288-0167-95 71288-0167 Pemetrexed disodium Pemetrexed 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
71288-0169-25 71288-0169 Cytarabine Cytarabine 20.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Feb 28, 2022 In Use
71288-0170-75 71288-0170 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Sep 24, 2024 In Use
71288-0171-11 71288-0171 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan 11, 2024 In Use
71288-0171-91 71288-0171 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan 11, 2024 In Use
71288-0172-21 71288-0172 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan 11, 2024 In Use
71288-0172-92 71288-0172 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan 11, 2024 In Use
71288-0174-21 71288-0174 Dacarbazine Dacarbazine 200.0 mg/20mL Chemotherapy Alkylating Agent Purine Analog Intravenous Apr 22, 2024 In Use
71288-0175-05 71288-0175 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Feb 1, 2025 In Use
71288-0176-25 71288-0176 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Feb 1, 2025 In Use
71288-0177-50 71288-0177 Etoposide Etoposide 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous Feb 1, 2025 In Use
71288-0178-10 71288-0178 mitoXANTRONE mitoXANTRONE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous Jun 1, 2025 In Use
71288-0179-13 71288-0179 mitoXANTRONE mitoXANTRONE 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous Jun 1, 2025 In Use
71288-0182-05 71288-0182 Daunorubicin hydrochloride Daunorubicin hydrochloride 5.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jun 1, 2025 In Use
71288-0183-50 71288-0183 Paclitaxel Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous May 15, 2025 In Use
71288-0184-05 71288-0184 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jun 1, 2025 In Use
71288-0185-10 71288-0185 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jun 1, 2025 In Use
71288-0186-20 71288-0186 Idarubicin Hydrochloride Idarubicin Hydrochloride 1.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Jun 1, 2025 In Use
71288-0409-05 71288-0409 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Aug 14, 2023 In Use
71288-0418-10 71288-0418 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov 15, 2019 Mar 30, 2023 No Longer Used

Found 11748 results — Export these results